SCYNEXIS, Inc., a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections. The company also develops SCY-078, which is in various Phase I studies for the oral and intravenous formulations, as well as has completed Phase II study as a step-down therapy in patients with invasive candidiasis and vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp. and R-Pharm, CJSC, to develop and commercialize rights for SCY-078. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Jersey City, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone201-884-5485
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$260,000.00
Profitability
Miscellaneous
Employees19
OptionableOptionable
SCYNEXIS (NASDAQ:SCYX) Frequently Asked Questions
What is SCYNEXIS's stock symbol?
SCYNEXIS trades on the NASDAQ under the ticker symbol "SCYX."
How were SCYNEXIS's earnings last quarter?
SCYNEXIS Inc (NASDAQ:SCYX) issued its quarterly earnings data on Tuesday, November, 13th. The company reported $0.01 EPS for the quarter, topping the Zacks' consensus estimate of ($0.17) by $0.18. The firm earned $0.06 million during the quarter, compared to the consensus estimate of $0.06 million. SCYNEXIS had a negative return on equity of 102.52% and a negative net margin of 8,592.97%. View SCYNEXIS's Earnings History.
When is SCYNEXIS's next earnings date?
What price target have analysts set for SCYX?
8 Wall Street analysts have issued 12 month price targets for SCYNEXIS's shares. Their predictions range from $4.00 to $9.00. On average, they anticipate SCYNEXIS's stock price to reach $5.2857 in the next year. This suggests a possible upside of 283.0% from the stock's current price. View Analyst Price Targets for SCYNEXIS.
What is the consensus analysts' recommendation for SCYNEXIS?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SCYNEXIS in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SCYNEXIS.
Has SCYNEXIS been receiving favorable news coverage?
News articles about SCYX stock have trended positive on Sunday, InfoTrie reports. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. SCYNEXIS earned a news sentiment score of 2.4 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the stock's share price in the near future.
Are investors shorting SCYNEXIS?
SCYNEXIS saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 1,579,870 shares, an increase of 27.7% from the January 15th total of 1,237,188 shares. Based on an average trading volume of 3,201,647 shares, the days-to-cover ratio is currently 0.5 days. Approximately 3.5% of the company's shares are sold short. View SCYNEXIS's Current Options Chain.
Who are some of SCYNEXIS's key competitors?
Some companies that are related to SCYNEXIS include Intec Pharma (NTEC), AC Immune (ACIU), Kadmon (KDMN), Seres Therapeutics (MCRB), Savara (SVRA), TapImmune (MRKR), Emisphere Technologies (EMIS), Kala Pharmaceuticals (KALA), Verastem (VSTM), Synlogic (SYBX), Kamada (KMDA), Paratek Pharmaceuticals (PRTK), MannKind (MNKD), Syros Pharmaceuticals (SYRS) and Acer Therapeutics (ACER).
Who are SCYNEXIS's key executives?
SCYNEXIS's management team includes the folowing people:
- Dr. Marco Taglietti, CEO, Pres & Director (Age 59)
- Mr. Eric Francois, Chief Financial Officer (Age 44)
- Mr. David Gonzalez Angulo, Chief Medical Officer (Age 54)
- Mr. Scott Sukenick J.D., Gen. Counsel & Corp. Sec. (Age 41)
Who are SCYNEXIS's major shareholders?
SCYNEXIS's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include National Asset Management Inc. (0.47%), Dimensional Fund Advisors LP (0.41%) and Two Sigma Investments LP (0.35%). Company insiders that own SCYNEXIS stock include David C Hastings, Eric Francois, Gonzalez David Angulo, Marco Taglietti and Scott Sukenick. View Institutional Ownership Trends for SCYNEXIS.
Which major investors are selling SCYNEXIS stock?
Which major investors are buying SCYNEXIS stock?
SCYX stock was bought by a variety of institutional investors in the last quarter, including Two Sigma Investments LP. Company insiders that have bought SCYNEXIS stock in the last two years include David C Hastings, Eric Francois, Gonzalez David Angulo, Marco Taglietti and Scott Sukenick. View Insider Buying and Selling for SCYNEXIS.
How do I buy shares of SCYNEXIS?
Shares of SCYX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is SCYNEXIS's stock price today?
One share of SCYX stock can currently be purchased for approximately $1.38.
How big of a company is SCYNEXIS?
SCYNEXIS has a market capitalization of $66.20 million and generates $260,000.00 in revenue each year. The company earns $-25,060,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis. SCYNEXIS employs 19 workers across the globe.
What is SCYNEXIS's official website?
How can I contact SCYNEXIS?
SCYNEXIS's mailing address is 1 EVERTRUST PLAZA 13TH FLOOR, JERSEY CITY NJ, 07302. The company can be reached via phone at 201-884-5485 or via email at [email protected]
MarketBeat Community Rating for SCYNEXIS (NASDAQ SCYX)
MarketBeat's community ratings are surveys of what our community members think about SCYNEXIS and other stocks. Vote "Outperform" if you believe SCYX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SCYX will underperform the S&P 500 over the long term. You may vote once every thirty days.
